Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) hit a new 52-week low on Thursday . The company traded as low as C$0.34 and last traded at C$0.34, with a volume of 9582 shares. The stock had previously closed at C$0.35.
Medicenna Therapeutics Price Performance
The stock’s 50-day moving average price is C$0.41 and its 200-day moving average price is C$0.64. The company has a market capitalization of C$32.30 million, a price-to-earnings ratio of -1.59 and a beta of 2.96. The company has a quick ratio of 4.65, a current ratio of 1.52 and a debt-to-equity ratio of 4.79.
Medicenna Therapeutics (TSE:MDNA – Get Free Report) last released its quarterly earnings results on Thursday, June 25th. The company reported C($0.05) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 219.30%. Equities research analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current year.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- MarketBeat Week in Review – 07/20- 07/24
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
